(Q45864880)

17 December 2017

title

Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors (English)

1 reference

17 December 2017

0 references

0 references

6

1 reference

17 December 2017

author name string

J Astermark

1

1 reference

17 December 2017

A Rocino

2

1 reference

17 December 2017

M Von Depka

3

1 reference

17 December 2017

H M Van Den Berg

4

1 reference

17 December 2017

A Gringeri

5

1 reference

17 December 2017

M Morado

7

1 reference

17 December 2017

R P Garrido

8

1 reference

17 December 2017

M Schiavoni

9

1 reference

17 December 2017

A Villar

10

1 reference

17 December 2017

J Windyga

11

1 reference

17 December 2017

EHTSB

12

1 reference

17 December 2017

publication date

1 January 2007

1 reference

17 December 2017

published in

Haemophilia

1 reference

17 December 2017

volume

13

1 reference

17 December 2017

issue

1

1 reference

17 December 2017

page(s)

38-45

1 reference

17 December 2017

The epidemiology of inhibitors in haemophilia A: a systematic review

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01403.X

Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01403.X

Immune tolerance: a synopsis of the international experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01403.X

Immune tolerance induction in patients with haemophilia A with inhibitors: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01403.X

Immunoadsorption for removal of inhibitors: update on treatments in Malmö-Lund between 1980 and 1995.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01403.X

Control of bleeding in patients with haemophilia A with inhibitors: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01403.X

Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. FEIBA Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01403.X

Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01403.X

Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: the advantages of early intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01403.X

rVIIa therapy to secure haemostasis during central line insertion in children with high-responding FVIII inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01403.X

The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01403.X

Mortality in patients with hemophilia. Changes in a Dutch population from 1986 to 1992 and 1973 to 1986.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01403.X

Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01403.X

Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01403.X

Safety profile of recombinant factor VIIa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01403.X

Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01403.X

Tailoring haemostatic treatment to patient requirements - an update on monitoring haemostatic response using thrombelastography

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01403.X

Understanding the hemostatic effects of recombinant factor VIIa by clot wave form analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01403.X

Monitoring the bioavailability of FEIBA with a thrombin generation assay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01403.X

Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01403.X

Platelet-dependent thrombin generation assay for monitoring the efficacy of recombinant Factor VIIa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01403.X

Major surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decision.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01403.X

A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01403.X

Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01403.X

A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01403.X

Monitoring haemophilia severity and treatment: new or old laboratory tests?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01403.X

Thrombin generation assay and other universal tests for monitoring haemophilia therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01403.X

Activated recombinant human coagulation factor VII therapy for intracranial hemorrhage in patients with hemophilia A or B with inhibitors. Results of the novoseven emergency-use program

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01403.X

10.1111/J.1365-2516.2006.01403.X

21 January 2018

Identifiers

DOI

1 reference

17 December 2017

1 reference

17 December 2017